{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:57:41Z","timestamp":1784185061451,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009655","name":"Sunovion Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.bbi.2018.08.009","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T03:03:07Z","timestamp":1533870187000},"page":"717-724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["C-reactive protein and response to lurasidone in patients with bipolar depression"],"prefix":"10.1016","volume":"73","author":[{"given":"Charles L.","family":"Raison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Pikalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Koblan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Loebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbi.2018.08.009_b0005","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1523\/JNEUROSCI.5826-11.2012","article-title":"Modulation of frontostriatal interaction aligns with reduced primary reward processing under serotonergic drugs","volume":"32","author":"Abler","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbi.2018.08.009_b0010","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.4088\/JCP.v65n1109","article-title":"Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample","volume":"65","author":"Calabrese","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbi.2018.08.009_b0015","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archgenpsychiatry.2011.2094","article-title":"Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration","volume":"69","author":"Capuron","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bbi.2018.08.009_b0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/npp.2012.191","article-title":"Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline \u201cpredictors\u201d and longitudinal \u201ctargets\u201d","volume":"38","author":"Cattaneo","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbi.2018.08.009_b0025","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bbi.2012.08.008","article-title":"Indoleamine 2,3-dioxygenase inhibition attenuates lipopolysaccharide induced persistent microglial activation and depressive-like complications in fractalkine receptor (CX(3)CR1)-deficient mice","volume":"31","author":"Corona","year":"2013","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2018.08.009_b0030","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nrn2297","article-title":"From inflammation to sickness and depression: when the immune system subjugates the brain","volume":"9","author":"Dantzer","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbi.2018.08.009_b0035","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4088\/JCP.14r09007","article-title":"C-reactive protein alterations in bipolar disorder: a meta-analysis","volume":"76","author":"Darg\u00e9l","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbi.2018.08.009_b0040","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.bbi.2009.12.009","article-title":"Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood","volume":"24","author":"Eisenberger","year":"2010","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2018.08.009_b0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jad.2013.02.001","article-title":"Prevalence, chronicity, burden and borders of bipolar disorder","volume":"148","author":"Fagiolini","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbi.2018.08.009_b0050","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/mp.2015.168","article-title":"Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression","volume":"21","author":"Felger","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbi.2018.08.009_b0055","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/mp.2015.87","article-title":"C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications","volume":"21","author":"Fernandes","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbi.2018.08.009_b0060","series-title":"Applied Longitudinal Analysis","author":"Fitzmaurice","year":"2004"},{"key":"10.1016\/j.bbi.2018.08.009_b0065","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/JCP.0000000000000596","article-title":"Subjective versus objective weight gain during acute treatment with second-generation antipsychotics in schizophrenia and bipolar disorder","volume":"36","author":"Gao","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbi.2018.08.009_b0070","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/npp.2014.226","article-title":"Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression","volume":"40","author":"Guilloux","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbi.2018.08.009_b0075","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/7854_2016_40","article-title":"Inflammation effects on brain glutamate in depression: mechanistic considerations and treatment implications","volume":"31","author":"Haroon","year":"2017","journal-title":"Current topics in behavioral neurosciences"},{"key":"10.1016\/j.bbi.2018.08.009_b0080","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jpsychires.2011.08.003","article-title":"Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia","volume":"45","author":"Hope","year":"2011","journal-title":"J. Psychiatry Res."},{"key":"10.1016\/j.bbi.2018.08.009_b0085","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/jnc.12512","article-title":"Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism","volume":"128","author":"Huang","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbi.2018.08.009_b0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbi.2016.09.014","article-title":"TNFAIP3, a negative regulator of the TLR signaling pathway, is a potential predictive biomarker of response to antidepressant treatment in major depressive disorder","volume":"59","author":"Hung","year":"2017","journal-title":"Brain Behav. Immun."},{"issue":"Suppl. 9","key":"10.1016\/j.bbi.2018.08.009_b0095","first-page":"47","article-title":"Suicide and bipolar disorder","volume":"61","author":"Jamison","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbi.2018.08.009_b0100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.psyneuen.2017.01.023","article-title":"Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial","volume":"78","author":"Jha","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.bbi.2018.08.009_b0105","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","article-title":"The long-term natural history of the weekly symptomatic status of bipolar I disorder","volume":"59","author":"Judd","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bbi.2018.08.009_b0110","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00210-010-0521-x","article-title":"Effects of bupropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats","volume":"382","author":"Kitamura","year":"2010","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.bbi.2018.08.009_b0115","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.biopsych.2006.10.001","article-title":"Overweight and obesity affect treatment response in major depression","volume":"62","author":"Kloiber","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2018.08.009_b0120","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1073\/pnas.0910658107","article-title":"Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior","volume":"107","author":"Koo","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbi.2018.08.009_b0125","doi-asserted-by":"crossref","first-page":"506","DOI":"10.4088\/JCP.v64n0503","article-title":"Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network","volume":"64","author":"Leverich","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbi.2018.08.009_b0130","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jad.2014.12.033","article-title":"IL-23 and TGF-\u03b21 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode","volume":"174","author":"Li","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbi.2018.08.009_b0135","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.bbr.2016.11.007","article-title":"Antidepressant-like effect of pramipexole in an inflammatory model of depression","volume":"320","author":"Lieberknecht","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbi.2018.08.009_b0140","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbi.2018.08.009_b0145","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1751-2980.2008.00335.x","article-title":"Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease","volume":"9","author":"Maharshak","year":"2008","journal-title":"J. Dig. Dis."},{"key":"10.1016\/j.bbi.2018.08.009_b0150","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1037\/0022-006X.68.3.438","article-title":"Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review","volume":"68","author":"Martin","year":"2000","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.bbi.2018.08.009_b0155","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ajhb.22296","article-title":"Analysis of variability of high sensitivity C-reactive protein in lowland Ecuador reveals no evidence of chronic low-grade inflammation","volume":"24","author":"McDade","year":"2012","journal-title":"Am. J. Hum. Biol."},{"key":"10.1016\/j.bbi.2018.08.009_b0160","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2018.08.009_b0165","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbi.2014.09.021","article-title":"Elevated levels of IL-6 and IL-18 in manic and hypomanic states in rapid cycling bipolar disorder patients","volume":"43","author":"Munkholm","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2018.08.009_b0170","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.bbi.2009.04.005","article-title":"To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers","volume":"23","author":"O\u2019Connor","year":"2009","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbi.2018.08.009_b0175","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/aje\/kws443","article-title":"Trends in C-reactive protein levels in US adults from 1999 to 2010","volume":"177","author":"Ong","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.bbi.2018.08.009_b0180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jad.2012.10.002","article-title":"Costs of the principal mood disorders: a study of comparative direct and indirect costs incurred by those with bipolar I, bipolar II and unipolar disorders","volume":"149","author":"Parker","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.bbi.2018.08.009_b0185","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.euroneuro.2016.06.007","article-title":"Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression","volume":"26","author":"Pettai","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbi.2018.08.009_b0190","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.euroneuro.2012.09.009","article-title":"Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response","volume":"23","author":"Powell","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.bbi.2018.08.009_b0195","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","article-title":"A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers","volume":"70","author":"Raison","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.bbi.2018.08.009_b0200","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/mp.2015.22","article-title":"Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study","volume":"21","author":"Rapaport","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbi.2018.08.009_b0205","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/01.CIR.0000053730.47739.3C","article-title":"Clinical application of C-reactive protein for cardiovascular disease detection and prevention","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.bbi.2018.08.009_b0210","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.encep.2016.06.005","article-title":"Clinical and biological predictors of ketamine response in treatment-resistant major depression: review","volume":"43","author":"Romeo","year":"2017","journal-title":"Encephale"},{"key":"10.1016\/j.bbi.2018.08.009_b0215","article-title":"Assessing effects of l-Methylfolate in depression management: results of a real-world patient experience trial","volume":"15","author":"Shelton","year":"2013","journal-title":"Prim Care Companion CNS Disord."},{"key":"10.1016\/j.bbi.2018.08.009_b0220","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4088\/JCP.09r05385gre","article-title":"Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis","volume":"72","author":"Sidor","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbi.2018.08.009_b0225","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bdi.12026","article-title":"Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review","volume":"15","author":"Sienaert","year":"2013","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.bbi.2018.08.009_b0230","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.schres.2013.10.011","article-title":"Antipsychotics\u2019 effects on blood levels of cytokines in schizophrenia: a meta-analysis","volume":"151","author":"Tourjman","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2018.08.009_b0235","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMsa065779","article-title":"Selective publication of antidepressant trials and its influence on apparent efficacy","volume":"358","author":"Turner","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbi.2018.08.009_b0240","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1176\/appi.ajp.2014.14010094","article-title":"An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline","volume":"171","author":"Uher","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbi.2018.08.009_b0245","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/npp.2013.71","article-title":"NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL\/6J mice","volume":"38","author":"Walker","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"77","key":"10.1016\/j.bbi.2018.08.009_b0250","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.biopsych.2014.06.021","article-title":"Serum interleukin-6 is a predictive biomarker for ketamine\u2019s antidepressant effect in treatment-resistant patients with major depression","volume":"1","author":"Yang","year":"2015","journal-title":"Biol. Psychiatry"}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159118304392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159118304392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:54:53Z","timestamp":1760169293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159118304392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":50,"alternative-id":["S0889159118304392"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2018.08.009","relation":{},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"C-reactive protein and response to lurasidone in patients with bipolar depression","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2018.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}